Krystal Biotech has successfully received critical approvals from the United States Food and Drug Administration (FDA) for its flagship product, VYJUVEK (beremagene geperpavec-svdt). VYJUVEK is a ground-breaking, redosable gene therapy indicated for the treatment of wounds in patients with dystrophic epidermolysis bullosa, a severe and debilitating genetic skin condition. Initially securing landmark approval for patients six months of age and older, the company subsequently obtained an expanded FDA label update allowing treatment for patients from birth and permitting home administration by patients or caregivers. Furthermore, the FDA has granted various pipeline assets advanced regulatory statuses, such as Regenerative Medicine Advanced Therapy (RMAT) designations and platform technology recognitions, underscoring the company's strong, compliant standing with regulatory authorities.